TB-500 has already popped up on this site — as one half of the BPC-157 + TB-500 stack and the Wolverine stack — but it’s never had a page of its own. That’s a gap, because plenty of people search for TB-500 specifically, not the combo. So let’s take it on its own terms: what it actually is, what the evidence supports, and — just as important — where that evidence quietly runs out.
What Is TB-500, Really?
TB-500 is a lab-made peptide built to copy the active region of Thymosin Beta-4 (Tβ4), a small protein that’s naturally present in almost every cell in your body. It’s genuinely everywhere — one of the most abundant proteins inside human cells, reaching remarkably high concentrations in certain tissue types. The name comes from where it was first isolated (thymus tissue), but don’t let that fool you — it’s not thymus-specific at all.
Making the full-length, 43-amino-acid Tβ4 protein is expensive, and the whole molecule is a bit unstable to work with. So researchers built TB-500 as a shorter synthetic piece — specifically the LKKTETQ sequence — that seems to hold onto most of the original’s biological activity. In practice, “TB-500” and “Thymosin Beta-4” get used interchangeably in most research writing, even though technically one is the synthetic fragment and the other is the full natural protein. One more wrinkle worth knowing: newer research from 2024 suggests TB-500’s wound-healing effects might actually come from a metabolite the body creates after breaking it down, rather than from the original peptide itself. That’s still an open question, and it matters because it means how your body processes TB-500 might be just as important as the molecule you actually inject.
So How’s It Supposed to Work?
TB-500’s whole story comes down to one protein: actin. Actin is the scaffolding that gives your cells their shape and lets them move around — and when tissue gets damaged, cells need to migrate to the injury site, multiply, and rebuild. Actin dynamics are what make that migration possible in the first place.
TB-500’s main studied job is binding and regulating actin, which effectively controls how easily cells can reorganize themselves and get moving toward an injury. That’s a genuinely different mechanism from BPC-157, which works mainly by boosting blood vessel growth and protecting tissue directly — which is exactly why the two get studied together, in our BPC-157 + TB-500 stack article, rather than treated as swappable for each other.
Beyond just cell movement, the research also points to a few other effects:
- Calming inflammation. Research from Sosne and colleagues (2007) found that Tβ4 suppresses a key inflammatory signaling pathway (NF-κB), giving a plausible explanation for reduced inflammation that’s separate from the cell-migration story.
- Waking up dormant heart cells. This one’s genuinely striking. Smart and colleagues (2007) found that Tβ4 activates dormant progenitor cells in the heart’s outer layer, prompting the formation of new heart muscle cells in adult mice after an induced injury. Adult mammalian hearts are famously bad at regenerating themselves, so this result got a lot of attention.
- New blood vessel growth. Tβ4 also promotes angiogenesis at injury sites, rounding out a picture of a compound that creates a broadly favorable environment for healing on multiple fronts at once.
What Does the Human Evidence Actually Show?
A 2026 scoping review dug through PubMed, Europe PMC, and ClinicalTrials.gov up to March 2026, and pulled out 80 relevant studies from an initial pool of 1,772 records specifically about Tβ4/TB-500 in tissue healing. Two things from that review are worth flagging up front: most of what’s out there leans toward mixed-design and in vitro work rather than controlled human trials, and a good chunk of the strongest studies are actually about Tβ4 — the natural, full-length protein — not TB-500 specifically. So some of what gets cited as “TB-500 evidence” is technically evidence for a closely related, but not identical, molecule.
Breaking the evidence down by what it’s actually been tested on:
Wound and eye healing — genuinely the strongest human data. RegeneRx Biopharmaceuticals has run actual Phase II trials on synthetic Tβ4 formulations — one for dry eye and corneal healing (RGN-259), one systemic (RGN-352). The eye trial showed real improvement in corneal staining scores. Separate trials in chronic and acute skin wounds showed faster wound closure. This is, hands down, the best-supported use case in the entire TB-500 literature — actual controlled human trials, not just animal extrapolation.
Heart repair — impressive in mice, untested in people. The Bock-Marquette et al. (2004, Nature) finding — smaller heart damage and better recovery after a heart attack in mice, driven by activating those dormant progenitor cells — is one of the most cited pieces of Tβ4 research out there. It’s compelling work. It has never progressed to a human cardiac trial.
Muscle and tendon repair — the most talked-about use, and the least directly supported. This is exactly the application driving most of the search interest in fitness and recovery communities, and ironically it’s the one with the thinnest direct evidence. What exists is mostly extrapolation: animal studies show TB-500 activates the stem-cell-like cells responsible for muscle regeneration, and the anti-inflammatory and blood-vessel effects seen elsewhere are a reasonable guess for how it might help tendons too. But an actual controlled human trial testing TB-500 specifically for musculoskeletal injury — the exact thing most people are looking it up for — doesn’t really exist in the published literature. One physician-authored review summed it up bluntly: biologically plausible, short-term safe in the data available, but not yet proven for orthopedic use — and suggested that something like platelet-rich plasma or a structured rehab program remains the better-evidenced choice for now.
A real safety study, but a narrow one. A Phase 1 trial in healthy volunteers found recombinant Tβ4 was well tolerated at both single and repeated intravenous doses, with no serious side effects or dose limits hit. That’s a meaningful proof of basic tolerability in humans — but it’s a safety study, not an effectiveness study, and it doesn’t validate any of the specific uses discussed above.
What Do Research Protocols Actually Use for Dosing?
Same approach we take everywhere on this site: this is a description of what’s shown up in published research, not a recommendation for use. Dosing varies wildly depending on the species and the goal. Equine sports medicine — one of the biggest real-world data sources for TB-500, thanks to extensive off-label veterinary use — has used loading doses around 10 mg every other day over roughly 30 days. Rodent wound studies have used much smaller amounts, in the microgram range applied directly to the wound. Rodent heart studies have used similarly small systemic doses.
These numbers illustrate just how much dosing protocols swing depending on species, delivery method, and what’s actually being studied — they’re not directly comparable to each other, let alone something you could translate into a human protocol. If you’re here for handling basics, our BAC water and reconstitution guide covers the general process once a research-grade peptide has been sourced, and our peptide storage guide notes that reconstituted TB-500 solutions are described as moderately stable — needing refrigeration and use within roughly three weeks.
TB-500 vs. BPC-157: Why They Get Paired but Aren’t the Same Thing
Since these two get mentioned together constantly, it’s worth being clear about what actually separates them. BPC-157 is a small, 15-amino-acid peptide derived from a protective sequence found in human gastric juice, and it’s mostly studied for blood vessel growth and protection concentrated in the gut and connective tissue. TB-500 is a piece of a much bigger, 43-amino-acid protein found in basically every cell type in the body, and it’s studied mainly for helping cells physically migrate to an injury. One’s tissue-specific in its origin story; the other is systemic. One’s best human evidence sits in gut and connective-tissue contexts; the other’s best human evidence is in wound healing and eye repair. Pairing them reflects a hypothesis about complementary mechanisms — not proof that they’re interchangeable or that one can stand in for the other. Our BPC-157 benefits article covers that compound’s evidence in the same tier-by-tier way this article just walked through for TB-500.
Is It Legal?
The FDA currently includes the TB4 fragment on its list of bulk substances considered to carry significant safety risks for pharmacy compounding, citing limited human safety data. Separately, the World Anti-Doping Agency bans TB4 and its derivatives, including TB-500, under its current Prohibited List — relevant if you’re connected to competitive sport in any way. Neither of these reflects a scientific verdict on whether TB-500 works. They’re regulatory and anti-doping risk classifications, which is a distinction worth keeping straight rather than blurring together.
Quick Questions
Is TB-500 literally the same as Thymosin Beta-4? Functionally, yes, for almost all practical purposes — TB-500 is the synthetic fragment built to replicate Tβ4’s active region, and the two terms get used interchangeably in most research writing.
Is it approved for any human use anywhere? No. The strongest data (RGN-259, RGN-352) comes from Phase II trials, but neither has completed the full path to FDA approval. TB-500 as sold through research-chemical channels isn’t an approved therapy.
If it’s not even an approved drug, why is it banned in sports? Anti-doping rules are based on a substance’s potential to enhance performance, not whether it’s medically approved — so something can be simultaneously unapproved for any medical use and banned in competition, which is exactly where TB-500 sits.
Bottom Line
TB-500’s evidence really is tiered, and it’s worth reading the compound that way instead of asking one flat “does it work” question. Wound healing and eye repair have genuine Phase II human trial backing. Heart repair has a striking mouse study and nothing beyond it. Muscle and tendon repair — the thing most people are actually here for — rests on animal data and a reasonable-sounding mechanism, without the human trials that would confirm it works for that specific use. A short Phase 1 study supports basic tolerability, but that’s a different claim from proving any particular benefit.
This is educational content based on published research and is not medical advice. TB-500 is not FDA-approved for human use, and nothing in this article should be read as a recommendation for personal use.